FindTrial
Sign In

Qingdaigao cream with NB-UVB effects on the level of il-17 and VEGF in patients with psoriasis vulgaris (blood type)

Qingdaigao cream with NB-UVB effects on the level of il-17 and VEGF in patients with psoriasis vulgaris (blood type)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015097
Enrollment
Unknown
Registered
2018-03-07
Start date
2018-04-01
Completion date
Unknown
Last updated
2018-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis vulgaris (blood type)

Interventions

Control group:External drug
Experimental group:qingdaigao ointment combined with NB-UVB

Sponsors

Gansu Province Hospital of Traditional Chinese Mediccine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) with psoriasis vulgaris diagnosis criteria and TCM symptoms consistent with blood heat type; (2) aged 18-65 years male and female; (3) no drug system treatment in the last half a year; (4) there is no serious heart, cerebrovascular, liver, kidney, and circulatory disease patients. (5) good compliance, can cooperate with the completion of the treatment of patients;

Exclusion criteria

Exclusion criteria: (1) the age is not in conformity with the inclusion criteria; (2) women at the stage of pregnancy or lactation; (3) the patients with serious heart, liver, lung, kidney, blood system and psychosis were combined; (4) the use of glucocorticoids or immunosuppressive agents and immunomodulators for 10 days.

Design outcomes

Primary

MeasureTime frame
IL-17 and VEGF levels;—

Countries

China

Contacts

Public ContactLi Heping

Gansu Province Hospital of Traditional Chinese Mediccine

peaseli@163.com+86 15193198859

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026